Interferon-gamma reduces the sensitivity of cultured and fresh human tumor cells to lysis by lymphokine-activated killer cells.
We have shown that interferon-gamma (IFN-gamma), in pharmacologically achievable doses, can reduce the the sensitivity of human tumor cells to lysis by allogeneic lymphokine-activated killer (LAK) effector cells. Cultured tumor cells showed a consistent reduction in sensitivity to lysis following pretreatment for 18 h with 1-10 units/ml IFN-gamma. Tumor cells cultured up to 7 days in 100 units/ml IFN-gamma remained less sensitive to lysis. Induction of protection from LAK did not appear to correlate with IFN-gamma-induced changes in cell growth or proliferation. Reduced LAK sensitivity also did not correlate with the level of expression of major histocompatibility antigens. Eight of 11 surgically obtained human tumor cell specimens showed a reduction in sensitivity to lysis by allogeneic LAK cells following pretreatment with IFN-gamma. IFN-induced reduction of tumor cell sensitivity to lysis by LAK may play a role in altering the host-tumor relationship, since relatively high concentrations of IFN-gamma may exist in the tumor microenvironment.
D002455:Cell Division; D003602:Cytotoxicity, Immunologic; D005260:Female; D005434:Flow Cytometry; D006680:HLA Antigens / Q000032:analysis; D006684:HLA-DR Antigens / Q000032:analysis; D006801:Humans; D007371:Interferon-gamma / Q000494:pharmacology*; D007376:Interleukin-2 / Q000494:pharmacology; D007694:Killer Cells, Natural / Q000276:immunology*; D013997:Time Factors; D014407:Tumor Cells, Cultured / Q000166:cytology / Q000276:immunology*
D006680:HLA Antigens; D006684:HLA-DR Antigens; D007376:Interleukin-2; D007371:Interferon-gamma